Aridis Pharmaceuticals (ARDS)
NASDAQ:ARDS
Aridis Pharmaceuticals Financial Statements
Aridis Pharmaceuticals Financial Overview
Aridis Pharmaceuticals's market cap is currently ―. The company's EPS TTM is $-3.787; its P/E ratio is -0.58; Aridis Pharmaceuticals is scheduled to report earnings on August 16, 2022, and the estimated EPS forecast is $-0.06. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ -131.00K | $ 98.00K | $ 33.00K | $ 0.00 |
| Gross Profit | $ ― | $ ― | $ ― | $ ― | $ ― |
| EBIT | $ -7.42M | $ -8.55M | $ -21.03M | $ -6.23M | $ -6.90M |
| EBITDA | $ -7.29M | $ -8.39M | $ -20.93M | $ -6.14M | $ -6.81M |
| Net Income Common Stockholders | $ -7.77M | $ -8.81M | $ -24.14M | $ -5.49M | $ -7.88M |
| Balance Sheet | |||||
| Cash, Cash Equivalents and Short-Term Investments | $ 3.59M | $ 6.21M | $ 8.23M | $ 10.47M | $ 12.47M |
| Total Assets | $ 23.82M | $ 26.80M | $ 26.09M | $ 11.39M | $ 17.57M |
| Total Debt | $ 466.00K | $ 715.00K | $ 964.00K | $ 5.91M | $ 13.05M |
| Net Debt | $ -3.13M | $ -5.50M | $ -7.27M | $ -4.56M | $ 579.00K |
| Total Liabilities | $ 44.23M | $ 39.91M | $ 30.24M | $ 24.87M | $ 26.12M |
| Stockholders Equity | $ -20.41M | $ -13.11M | $ -4.16M | $ -13.49M | $ -8.55M |
| Cash Flow | |||||
| Free Cash Flow | $ -10.19M | $ -3.69M | $ -8.71M | $ -6.73M | $ -4.34M |
| Operating Cash Flow | $ -10.17M | $ -3.73M | $ -8.59M | $ -6.61M | $ -4.01M |
| Investing Cash Flow | $ -21.00K | $ 43.00K | $ -114.00K | $ -124.00K | $ -335.00K |
| Financing Cash Flow | $ 4.44M | $ 4.95M | $ 23.34M | $ -149.00K | $ 6.58M |
Aridis Pharmaceuticals Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.